Lung cancer is the leading cause of cancer death worldwide. Diagnosis of early-stage disease is becoming more common. In an aging population, more and more patients have substantial comorbidities that might limit feasibility of surgical management of early-stage disease. Stereotactic body radiotherapy (SBRT) enables delivery of high-dose, precisely delivered radiation to early-stage lung cancers without surgical risk. This technique has rates of local control similar to surgery and can be considered in medically operable patients who refuse surgery. This article details the technique of SBRT, the data for its efficacy, as well as the potential toxicities of treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ccm.2020.02.001 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!